Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Given its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings.

Which Is A Better Pick: JNJ Stock Or AbbVie?

Archer-Daniels-Midland Company

Avis Budget Group

Constellation Energy Corp

ConocoPhillips

Cisco Systems

CVS Health

Energy Transfer LP Unit

Halliburton

JPMorgan Chase & Co

Coca-Cola

Kroger

Altria

NIKE

Omnicom Group

PepsiCo

Prologis

Southern Company

AT&T

Exxon Mobil

AT&T, Altria Group, and Energy Transfer are top buys with dividends from $1K invested exceeding single share prices, meeting the dogcatcher ideal. Analysts forecast 15.47% to 28.33% net gains by November 2025 for top-ten F500IL dogs, with Energy Transfer as the standout “safer” choice. Eight F500IL stocks show negative free cash flow margins, making them unsafe buys; price drops or dividend increases could make top-yield F500IL fair-priced.

Of 63 Fortune 500 Industry Leaders, 57 Pay Dividends, 38 Are Cash Rich And 1 Is A Buy

The decline in J&J's share price and the drug/biotech sector's downturn in the past month have left investors wondering if they should sell J&J stock.

J&J Loses Around $24B in a Month: How to Play the Stock?

Pfizer

Verizon

I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Both pay an attractive Dividend Yield [FWD] of 6.14% (Pfizer) and 6.58% (Verizon) and have a relatively low Valuation (P/E Non-GAAP [FWD] Ratio of 9.34 (Pfizer) and 8.80 (Verizon). To reduce the company-specific concentration risk of your investment portfolio, I suggest setting an allocation limit of 3% for both companies.

If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%

The Health Care sector faces uncertainty due to speculation about Robert F. Kennedy, Jr. leading HHS, impacting stocks like Johnson & Johnson. Despite solid earnings, JNJ shares have been under pressure; I maintain a buy rating due to undervaluation and a strong dividend yield. Key risks include health care policy changes, global economic conditions, and competition, but JNJ's revenue and earnings forecasts remain optimistic.

Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

More than 90 presentations of clinical trial and real-world data highlight potentially practice-changing evidence and commitment to pioneer the next wave of therapies for patients with hematologic malignancies RARITAN, N.J. , Nov. 19, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of  Hematology (ASH) Annual Meeting in San Diego from December 7-10.

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

Johnson & Johnson's drug for a type of skin condition met the main goals in a late-stage trial, the drugmaker said on Monday.

J&J's skin disease drug meets main goals of late-stage study

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 Comprehensive results are being prepared for presentation at upcoming medical congresses SPRING HOUSE, Pa. , Nov. 18, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEAD a, a pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO).

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 ICONIC-TOTAL achieved its primary endpoint of IGA score of 0 or 1 at week 16 in patients with plaque psoriasis in difficult-to-treat areas Protagonist has earned a $165 million milestone under the terms of recently amended agreement, inclusive of $50 million in accelerated payments NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from its collaboration with Johnson & Johnson, in ICONIC-LEAD 1 and ICONIC-TOTAL 2, two pivotal Phase 3 investigational studies of icotrokinra (JNJ-2113, formerly PN-235), the first-in-class targeted oral peptide that selectively blocks the IL-23 receptor, in individuals 12 years of age and older with moderate to severe plaque psoriasis (PsO). In the ICONIC-LEAD study, once-daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis.

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor

Johnson & Johnson (NYSE:JNJ ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET Company Participants Michael Bodner - Group President, Heart Recovery and Circulatory Restoration Conference Call Participants Rick Wise - Stifel Rick Wise Okay everybody, Rick Wise again here and it is my pleasure and truly my privilege to welcome J&J to the 2024 Stifel Healthcare Conference. To my left, Michael Bodner, Group President, Heart Recovery and Circulatory Restoration.

Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

GlaxoSmithKline

Eli Lilly

Merck

Moderna

Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.

As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.

Johnson & Johnson (NYSE:JNJ ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wildgust - VP, Global Medical Affairs Oncology Conference Call Participants Vamil Divan - Guggenheim Securities Edouard Mullarky - Guggenheim Securities Vamil Divan All right. I think we're ready to get started.

Johnson & Johnson (JNJ) Guggenheim Global Healthcare Conference (Transcript)

Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.

Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program

Rexford Industrial Realty

In today's market, sticky inflation and elevated valuations make stock picking a challenge. But some dividend stocks still stand out as strong, long-term picks. These two dividend stocks offer growth potential and inflation protection. They're built to thrive in today's economic climate, offering stability and income. Even with market volatility, these picks have the ability to deliver consistent returns. Their solid fundamentals and strong business models provide confidence.

2 Of The Cheapest, High-Quality Dividend Stocks On The Market

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS study WASHINGTON , Nov. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% following treatment with investigational nipocalimab in adult patients with moderate-to-severe Sjögren's disease (SjD). These data were included in a plenary session presentation (Abstract #2527) and two posters (Abstracts #1427 and #2294) and are among the Company's 43 oral and poster presentations at the American College of Rheumatology (ACR) Convergence 2024.

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

In the second half of 2024, Johnson & Johnson made significant progress in developing its oncology franchise. So, Darzalex sales were $3.02 billion in the third quarter of 2024, up 20.7% year-on-year, thanks in part to its label expansions. Moreover, on November 8, 2024, the company announced the filing of regulatory applications to the FDA and EMA seeking approval of Darzalex Faspro for the treatment of high-risk smoldering MM.

Johnson & Johnson: Tracking Well Above The Industry

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study A greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants on average who received nipocalimab 15 mg/kg compared to participants who received placebo Nipocalimab was granted BTD in hemolytic disease of the fetus and newborn earlier this year, making this the second time Johnson & Johnson's nipocalimab has received this designation SPRING HOUSE, Pa. , Nov. 11, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe Sjögren's disease (SjD), a debilitating and chronic autoantibody disease with high prevalence, for which no approved advanced treatments are available.1,2,3,4 Nipocalimab is the only investigational therapy to secure this designation in SjD.

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Johnson & Johnson Enters Oversold Territory

Albemarle

Amcor Plc

Air Products and Chemicals

Atmos Energy

Franklin Resources

C.H. Robinson Worldwide

Chevron

Con Ed

Federal Realty Investment Trust

November's top-yielding Aristocrats include Franklin Resources, Amcor, Hormel, and Kenvue, meeting the dogcatcher ideal of dividends from $1K invested exceeding single share prices. Analysts forecast 12.5% to 20.12% net gains from the top-ten Aristocrat Dogs by November 2025, with NextEra Energy and Target leading the projections. Seven more Aristocrats, including Realty Income and Chevron, are within 50% of meeting the ideal dividend-to-price ratio, potentially becoming fair priced with market pressure.

News for Johnson & Johnson Stock (JNJ)